Quick Answer
10x Genomics, Inc. reported Diluted EPS of $0.35 per share (loss) for fiscal year 2025.
10x Genomics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.35 | +77.0% |
| 2024 | -$1.52 | +30.3% |
| 2023 | -$2.18 | -49.3% |
| 2022 | -$1.46 | -175.5% |
| 2021 | -$0.53 | +90.1% |
| 2020 | -$5.37 | -571.2% |
| 2019 | -$0.80 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.22 | +26.7% | -178.6% |
| June 30, 2025 | $0.28 | +187.5% | +200.0% |
| March 31, 2025 | -$0.28 | +44.0% | +6.7% |
| September 30, 2024 | -$0.30 | +62.0% | +6.3% |
| June 30, 2024 | -$0.32 | +39.6% | +36.0% |
| March 31, 2024 | -$0.50 | -13.6% | +36.7% |
| September 30, 2023 | -$0.79 | -113.5% | -49.1% |
| June 30, 2023 | -$0.53 | +7.0% | -20.5% |
- 10x Genomics, Inc. showed an increase of +77.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, 10x Genomics, Inc.’s diluted eps has grown by 56.2% (from $0.80 per share (loss) to $0.35 per share (loss)).
- The most recent figure is from 10x Genomics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: